SOLID STATE COMPATIBILITY STUDIES BETWEEN MONTELUKAST SODIUM AND LEVOCETIRIZINE
Â Objective: The aim of this research is to evaluate montelukast (MNT)-levocetirizine (LVZ) incompatibility when they gather in one solid dosage form.
Methods: Both drugs and their binary mixture (2:1) (MNT-LVZ) were subjected to the following condition: 25Â°C/60% RH and 40Â°C/75% RH for 14 weeks. Samples were withdrawn and analyzed using stability-indicating high-performance liquid chromatography (HPLC) method at time intervals (0, 1, 4, 14 weeks). Further investigations were carried out using differential scanning calorimeter (DSC), Fourier transform infrared (FTIR), and X-ray powder diffraction (XRPD)
Result: On the basis of HPLC results, the degradation percentage of both drugs in binary mixtures was <10% indicating no chemical interaction; this was confirmed by all FTIR results except new band 668 cmâˆ’1 appeared in the spectrum of the mixture after storing 14 weeks at 40Â°C/75% RH, revealing possible hydrogen bond formed in the mixture. DSC and XRPD revealed possible physical interaction including phase transformation (release the acid form of montelukast and basic form of levocetirizine and sodium chloride in the medium); this may affect dissolution rate and bioavailability.
Conclusion: The results obtained from this research gave an evidence to formulate MNT and LVZ in stable fixed-dose combination for the effective treatment of allergic diseases
2. National Institutes of Health. IgE and mast cells in allergic disease. ??? 2013;18:693-704.
3. Saini S, Nanda A, Hooda M, Dhari J. Formulation and evaluation of mouth dissolving anti-allergic tablets of levocetrizine dihydrochloride. J Chem Pharm Res 2011;3:450-5.
4. Merck Research Laboratories. Montelukast, SINGULAIR Â®; 2016.
5. Moiz M, Sirnivas P, Mamidi S. Formulation and evaluation of bilayered tablets of montelukast and levocetrizine dihydrochloride Using natural and synthetic polymers. Int J Drug Deliv 2011;3:597-618.
6. Gautam CS, Saha L. Letter to the Editors Fixed dose drug combinations (FDCs): Rational or irrational : A view point. Br J Clin Pharmacol 2007;65:795-6.
7. Pharmaceutica North America I. Material Safety Data Sheet, Levocetirizine Dihydrochloride; 2014.
8. USP. Material Safety Data Sheet, Montelukast Sodium; 2012. p. 1-6.
9. Arjanne OV, Dennie JM, Den Heavel V. Boxmer, Inventors; Synthon BV, Nijmegen Assignee. Solid-State Montelukast. US Patent No 7,553,853; 2009.
10. Montelukast Sodium. Japanese Pharmacopoeia (JP17).
11. Shinde AJ, Misale GM, Salokhe SV. Development and evaluation of bilayer mucoahesive gastroretentive tablet of diltiazem hydrochloride. Int J Pharm Pharm Sci 2014;6:365-70.
12. Gabbott P. A practical introduction to differential scanning calorimetry. In: Principles and Applications of Thermal Analysis. 1st ed. Ames, Iowa: Blackwell; 2008. p. 21-4.
13. Thumma S, Repka MA. Compatibility studies of promethazine hydrochloride with tablet excipients by means of thermal and non- thermal methods. Pharmazie 2009;64:183-9.
14. TiÅ£a B, FuliaÅŸ A, Bandur G, Marian E, TiÅ£a D. Compatibility study between ketoprofen and pharmaceutical excipients used in solid dosage forms. J Pharm Biomed Anal 2011;56:221-7.
15. Blatchford C, Saunders M, Potluri K, Gaisford S, Buckton G. Assessment of the Re-Crystallisation Behaviour of Micronised Alpha- Lactose Monohydrate. London, United Kingdom: Pharmaterials Ltd, The London School of Pharmacy; ???.
16. Raju K. FTIR studies of hydrogen bonding interaction between the hydroxyl and carbonyl liquids. Adv Appl Sci Res 2015;6:44-52.
17. Umeda Y, Fukami T, Furuishi T, Suzuki T, Makimura M, Tomono K, et al. Molecular complex consisting of two typical external medicines: Intermolecular interaction between indomethacin and lidocaine. Chem Pharm Bull (Tokyo) 2007;55:832-6.
18. Ghorab M, Gardouh A, Gad S. Effect of viscosity, surfactant typr and concentration on physiochemical properties of solid lipod nanoparticles. Int J Pharm Pharm Sci 2015;7:145-53.
19. Sunil SA, Srikanth MV, Rao NS, Raju V, Murthy KV. Investigation on in vitro dissolution rate enhancement of indomethacin by using a novel carrier sucrose fatty acid ester. Daru 2012;20:4.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.